BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies

Phase 1

Recruiting

Conditions: Neoplasms
Hepatic Insufficiency

Interventions: Drug: Onureg

First Posted Date: 2022-01-26

Last Posted Date: 2024-11-05

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 32

Registration Number: NCT05209295

Locations: 🇦🇷
Hospital Universitario Austral, Pilar, Buenos Aires, Argentina
🇨🇴
Instituto Nacional De Cancerologia, Bogota, Cundinamarca, Colombia
🇺🇸
University of Iowa, Iowa City, Iowa, United States

and more 19 locations

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission

Phase 2

Active, not recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Oral Azacitidine
Other: Placebo

First Posted Date: 2022-01-19

Last Posted Date: 2025-02-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 19

Registration Number: NCT05197426

Locations: 🇺🇸
Local Institution - 0011, Huntsville, Alabama, United States
🇯🇵
Local Institution - 0017, Nagoya, Aichi, Japan
🇯🇵
Local Institution - 0023, Nagoya, Aichi, Japan

and more 28 locations

Expanded Access for Apixaban

First Posted Date: 2022-01-11

Last Posted Date: 2022-03-18

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT05187286

Locations: 🇺🇸
Childrens Hospital Of Philadelphia, Philadelphia, Pennsylvania, United States

Expanded Access for Fixed-Dose Combination of Nivolumab Plus Relatlimab

First Posted Date: 2021-12-28

Last Posted Date: 2022-04-28

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT05170685

Expanded Access for Abatacept

First Posted Date: 2021-12-28

Last Posted Date: 2022-05-10

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT05170672

Locations: 🇺🇸
Local Institution - 0001, Austin, Texas, United States
🇧🇪
Local Institution - 0002, Leuven, Vlaams-brabant, Belgium

Expanded Access for Relatlimab

First Posted Date: 2021-12-28

Last Posted Date: 2022-04-28

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT05170659

A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer

Phase 2

Completed

Conditions: Prostatic Neoplasms, Castration-Resistant

Interventions: Biological: BMS-986218
Drug: Docetaxel
Biological: Nivolumab

First Posted Date: 2021-12-27

Last Posted Date: 2023-12-13

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 10

Registration Number: NCT05169684

Locations: 🇺🇸
Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
🇨🇦
Local Institution - 0028, Toronto, Ontario, Canada
🇺🇸
The Winship Cancer Institute of Emory University, Atlanta, Georgia, United States

and more 66 locations

A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring

Recruiting

Conditions: Multiple Sclerosis

First Posted Date: 2021-12-27

Last Posted Date: 2025-05-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1182

Registration Number: NCT05170126

Locations: 🇺🇸
ZEPOSIA MS Pregnancy Registry, Wilmington, North Carolina, United States
🇩🇪
Marienhospital Herne, Klinikum Der Ruhr-Universitaet Bochum, Herne, Germany

A Study of Preferences of Participants and Oncologists for the Characteristics of the Treatment for Renal Cell Carcinoma (RCC) In Spain And Portugal

Completed

Conditions: Renal Cell Carcinoma

First Posted Date: 2021-12-23

Last Posted Date: 2021-12-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 105

Registration Number: NCT05168436

Locations: 🇪🇸
Local Institution, Castellon de La Plana, Spain

A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes

Phase 1

Active, not recruiting

Conditions: Myelodysplastic Syndromes
Leukemia, Myeloid, Acute

Interventions: Drug: Venetoclax
Drug: CC-95251
Drug: Azacitidine

First Posted Date: 2021-12-23

Last Posted Date: 2024-04-02

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 218

Registration Number: NCT05168202

Locations: 🇺🇸
Local Institution - 0001, Houston, Texas, United States
🇦🇺
Local Institution - 0027, Wollongong, New South Wales, Australia
🇦🇺
Local Institution - 0006, Clayton, Victoria, Australia

and more 29 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy